Physician profile
Amy Akel
NPI 1326613183
$3,342.99
in general payments reported to CMS, 2019-2025
22 companies · $102 in 2025
The $102 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $287 · 2022: $1,199 · 2023: $751 · 2024: $1,004 · 2025: $102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,857.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,857.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,630.66 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $449.67 | 2021-2024 | Vraylar |
| Amgen INC. | $217.15 | 2021-2025 | Otezla, Repatha, Otezla |
| Lilly USA, LLC | $190.22 | 2021-2024 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $165.47 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $133.05 | 2021-2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.16 | 2021-2022 | |
| Astellas Pharma US INC | $67.11 | 2022-2023 | Myrbetriq |
| Sumitomo Pharma America, INC. | $58.63 | 2023-2024 | Gemtesa |
| Exact Sciences Corporation | $51.38 | 2023-2024 | Cologuard Collection Kit |
| Sunovion Pharmaceuticals INC. | $49.55 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $43.53 | 2022 | |
| Dexcom, INC. | $39.12 | 2021-2024 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $32.71 | 2022-2024 | |
| Kowa Pharmaceuticals America, INC. | $25.45 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zealand Pharma US, INC. | $23.96 | 2022 | |
| Insulet Corporation | $20.42 | 2022 | |
| Pfizer INC. | $15.84 | 2024 | |
| Indivior INC. | $15.56 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $15.05 | 2024 | Eliquis |
| Phathom Pharmaceuticals, INC. | $14.11 | 2024 | Voquezna |
| Mannkind Corporation | $12.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Akel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.